Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Vincent

Showing results (891-900 of 968) with videos related to

Pageof 97
Sort By:
Leukemia|October 14, 2024
Functional variant rs9344 at 11q13.3 regulates CCND1 expression in multiple myeloma with t(11;14)Hongwei Tang, Huihuang Yan, Suganti Shivaram, et al.
Leukemia|February 28, 2018
Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosisSurbhi Sidana, Nidhi Tandon, Angela Dispenzieri, et al.
Blood Cancer Journal|June 14, 2018
Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteriaArjun Lakshman, S Vincent Rajkumar, Francis K Buadi, et al.
Blood Cancer Journal|February 27, 2020
Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosisAngela Dispenzieri, Bonnie Arendt, Surendra Dasari, et al.
British Journal of Haematology|August 9, 2017
Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemiaJonas Paludo, Jithma P Abeykoon, Shaji Kumar, et al.
Blood Cancer Journal|August 7, 2019
Association of elevated serumfree light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosisAlyssa I Clay-Gilmour, Abdul R Rishi, Lynn R Goldin, et al.
JACC. Cardiooncology|April 22, 2026
Cardiac Biomarker Complete Response in AL Amyloidosis: Characteristics, Cardiac Recovery, and Survival of 63 PatientsEli Muchtar, Susan Geyer, Angela Dispenzieri, et al.
Mayo Clinic Proceedings|August 12, 2006
Mayo clinic consensus statement for the use of bisphosphonates in multiple myelomaMartha Q Lacy, Angela Dispenzieri, Morie A Gertz, et al.
Blood Advances|June 23, 2022
Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosisEli Muchtar, Morie A Gertz, Betsy R LaPlant, et al.
Mayo Clinic Proceedings|August 8, 2015
Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus StatementAngela Dispenzieri, Francis Buadi, Shaji K Kumar, et al.
Pageof 97

Showing results (891-900 of 968) with videos related to

Sort By:
Pageof 97
Leukemia|October 14, 2024
Functional variant rs9344 at 11q13.3 regulates CCND1 expression in multiple myeloma with t(11;14)Hongwei Tang, Huihuang Yan, Suganti Shivaram, et al.
Leukemia|February 28, 2018
Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosisSurbhi Sidana, Nidhi Tandon, Angela Dispenzieri, et al.
Blood Cancer Journal|June 14, 2018
Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteriaArjun Lakshman, S Vincent Rajkumar, Francis K Buadi, et al.
Blood Cancer Journal|February 27, 2020
Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosisAngela Dispenzieri, Bonnie Arendt, Surendra Dasari, et al.
British Journal of Haematology|August 9, 2017
Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemiaJonas Paludo, Jithma P Abeykoon, Shaji Kumar, et al.
Blood Cancer Journal|August 7, 2019
Association of elevated serumfree light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosisAlyssa I Clay-Gilmour, Abdul R Rishi, Lynn R Goldin, et al.
JACC. Cardiooncology|April 22, 2026
Cardiac Biomarker Complete Response in AL Amyloidosis: Characteristics, Cardiac Recovery, and Survival of 63 PatientsEli Muchtar, Susan Geyer, Angela Dispenzieri, et al.
Mayo Clinic Proceedings|August 12, 2006
Mayo clinic consensus statement for the use of bisphosphonates in multiple myelomaMartha Q Lacy, Angela Dispenzieri, Morie A Gertz, et al.
Blood Advances|June 23, 2022
Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosisEli Muchtar, Morie A Gertz, Betsy R LaPlant, et al.
Mayo Clinic Proceedings|August 8, 2015
Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus StatementAngela Dispenzieri, Francis Buadi, Shaji K Kumar, et al.
Pageof 97